RxDoctor Payments Data

Jessie Coleman

Internal Medicine · Kennewick, WANPI 1679932347

Payments from drug & device makers

$689in general payments, 2019–2025

Across 42 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$169
  • Sanofi-aventis U.S. LLC$103
  • Boehringer Ingelheim$100
  • Scilex Pharmaceuticals Inc.$77
  • Lilly USA, LLC$70
  • Johnson & Johnson$59
  • plus $111 from 6 others

What the payments were for

  • Food & beverage$66096%
  • Education$294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$689 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$5,251
Medicare patients
24
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$36,946
Spiriva RespimatTiotropium Bromide57$34,420
JardianceEmpagliflozin71$31,025
PradaxaDabigatran Etexilate Mesylate110$21,983
Wixela InhubFluticasone Propion/Salmeterol87$19,691
XareltoRivaroxaban13$16,735
EliquisApixaban15$15,339
MyrbetriqMirabegron16$14,704
Humulin NInsulin Nph Human Isophane60$11,538
ShingrixVaricella-Zoster Ge/As01b/Pf50$10,000
Stiolto RespimatTiotropium Br/Olodaterol Hcl13$9,162
Humalog Kwikpen U-100Insulin Lispro11$7,601
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen245$6,769
Atorvastatin Calcium605$6,765
Levothyroxine Sodium354$6,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Jardiance, Pradaxa, Stiolto Respimat$100$96,589251 claims
Novo NordiskOzempic$169$36,94646 claims
Johnson & JohnsonXarelto$59$16,73513 claims
PfizerEliquis$14$15,33915 claims
Astellas Pharma US IncMyrbetriq$29$14,70416 claims
Lilly USA, LLCHumulin N$70$11,53860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Kennewick

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →